These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22577058)

  • 1. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
    Hildebrandt MA; Lippman SM; Etzel CJ; Kim E; Lee JJ; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
    Clin Cancer Res; 2012 Jul; 18(13):3705-13. PubMed ID: 22577058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients.
    Lee JJ; Wu X; Hildebrandt MA; Yang H; Khuri FR; Kim E; Gu J; Ye Y; Lotan R; Spitz MR; Hong WK
    Cancer Prev Res (Phila); 2011 Feb; 4(2):185-93. PubMed ID: 21292633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants.
    Wu X; Spitz MR; Lee JJ; Lippman SM; Ye Y; Yang H; Khuri FR; Kim E; Gu J; Lotan R; Hong WK
    Cancer Prev Res (Phila); 2009 Jul; 2(7):617-24. PubMed ID: 19584075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.
    Wang J; Lippman SM; Lee JJ; Yang H; Khuri FR; Kim E; Lin J; Chang DW; Lotan R; Hong WK; Wu X
    Carcinogenesis; 2010 Oct; 31(10):1755-61. PubMed ID: 20627871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
    Khuri FR; Kim ES; Lee JJ; Winn RJ; Benner SE; Lippman SM; Fu KK; Cooper JS; Vokes EE; Chamberlain RM; Williams B; Pajak TF; Goepfert H; Hong WK
    Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):823-9. PubMed ID: 11489748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590).
    Bhatia AK; Lee JW; Pinto HA; Jacobs CD; Limburg PJ; Rubin P; Arusell RM; Dunphy EP; Khandekar JD; Reiner SA; Baez-Diaz L; Celano P; Li S; Li Y; Burtness BA; Adams GL; Pandya KJ
    Cancer; 2017 Dec; 123(23):4653-4662. PubMed ID: 28786105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strong case for personalized, targeted cancer prevention.
    Dawson MI
    Cancer Prev Res (Phila); 2011 Feb; 4(2):173-6. PubMed ID: 21292632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
    Toma S; Bonelli L; Sartoris A; Mira E; Antonelli A; Beatrice F; Giordano C; Benazzo M; Caroggio A; Cavalot AL; Gandolfo S; Garozzo A; Margarino G; Schenone G; Spadini N; Sirotovà Z; Zibordi F; Balzarini F; Serafini I; Miani P; Cortesina G
    Oncol Rep; 2004 Jun; 11(6):1297-305. PubMed ID: 15138569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
    Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
    J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
    Zhang X; Yang H; Lee JJ; Kim E; Lippman SM; Khuri FR; Spitz MR; Lotan R; Hong WK; Wu X
    Carcinogenesis; 2010 Dec; 31(12):2118-23. PubMed ID: 20819778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of head and neck cancer with retinoids: a negative result.
    Perry CF; Stevens M; Rabie I; Yarker ME; Cochrane J; Perry E; Traficante R; Coman W
    Arch Otolaryngol Head Neck Surg; 2005 Mar; 131(3):198-203. PubMed ID: 15781758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer.
    Minard CG; Spitz MR; Wu X; Hong WK; Etzel CJ
    Cancer; 2006 Jun; 106(12):2636-44. PubMed ID: 16703596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
    Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
    Khuri FR; Lee JJ; Lippman SM; Kim ES; Cooper JS; Benner SE; Winn R; Pajak TF; Williams B; Shenouda G; Hodson I; Fu K; Shin DM; Vokes EE; Feng L; Goepfert H; Hong WK
    J Natl Cancer Inst; 2006 Apr; 98(7):441-50. PubMed ID: 16595780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma.
    Pedrero JM; Carracedo DG; Pinto CM; Zapatero AH; Rodrigo JP; Nieto CS; Gonzalez MV
    Int J Cancer; 2005 Mar; 114(2):242-8. PubMed ID: 15543611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer.
    Wu X; Gu J; Dong Q; Huang M; Do KA; Hong WK; Spitz MR
    Clin Cancer Res; 2006 Dec; 12(23):7194-201. PubMed ID: 17145846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.
    Huang CI; Wang CC; Tai TS; Hwang TZ; Yang CC; Hsu CM; Su YC
    PLoS One; 2019; 14(11):e0225537. PubMed ID: 31756179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.